Study Demonstrates Feasibility of Tracking Mutations in Multiple Genes with Circulating Tumor DNA

May 30, 2012

|

NEW YORK (GenomeWeb News) – In Science Translational Medicine, researchers from the UK and the US have demonstrated the feasibility of doing blood-based 'liquid biopsies' using a targeted deep sequencing strategy that can uncover mutations in several genes using tumor DNA that is circulating in the bloodstream.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Commission to Develop Report on Germline Editing

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

Possible Effect of Border DNA Testing

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

To Boost Productivity

The US Department of Agriculture presents a new blueprint for animal genomic research.

This Week in Genome Research

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.

Featured White Papers

Compatibility of liquid biopsy assays on multiple sequencing platforms

BlueBee Data Security & Compliance

Jun

11

Featured Webinar

The Promise of Liquid Biopsy in Lung Cancer Monitoring

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Jun

19

Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Menu